AgingResearch.NewsJoin free

Phase 2Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

A Phase II, Double-Masked, Randomised, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy OF Non-Proliferative Type (NPDR)

Sponsor
Vantage Biosciences Ltd (Industry)
Enrolment
100 planned
Conditions
Diabetic Retinopathy; NPDR - Non Proliferative Diabetic Retinopathy
Interventions
VX-01; Placebo
Ages
adults, older adults
Registry
NCT06770933

Full record on ClinicalTrials.gov

From the registry

The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.

Primary outcomes

  • Evaluate the efficacy of oral doses of VX-01 in subjects compared to placebo following 1 year of treatment.

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered